Announced details
Treatment of muscular dystrophy, including LAMA2-related muscular dystrophy (LAMA2-RD)
The recipient of the notice of a decision to grant a patent for the patent application developed and filed by the company.
Japan’s patent administration authority.
Publication No.: 特表2026-519313. Patent registration number and term: Not disclosed
The company believes this is significant for protecting the future business value of MDL-101. Specific amount of the impact on results: Not disclosed
The company does not address Contract Value / Offering price.
Japan Patent Office (JPO)
| Item | Details |
|---|---|
| Names of Products / Services Covered | MDL-101, CRISPR-GNDM® |
| Counterparty | Japan Patent Office (JPO) |
| Counterparty overview | Japan’s patent administration authority. |
| Relationship with the Company | The recipient of the notice of a decision to grant a patent for the patent application developed and filed by the company. |
| Applicable area | Treatment of muscular dystrophy, including LAMA2-related muscular dystrophy (LAMA2-RD) |
| Registration number and expiry date | Publication No.: 特表2026-519313. Patent registration number and term: Not disclosed |
| Impact on Business Performance | The company believes this is significant for protecting the future business value of MDL-101. Specific amount of the impact on results: Not disclosed |
| Source | Japan Patent Office (JPO) |
Items this document does not state (10)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The patent grant in Japan will strengthen the intellectual property foundation for the LAMA2-RD treatment approach using CRISPR-GNDM® and protect the future business value of MDL-101.